Celsion Corporation (CLSN) Scheduled to Post Quarterly Earnings on Tuesday

Celsion Corporation (NASDAQ:CLSN) is set to issue its quarterly earnings data before the market opens on Tuesday, November 14th. Analysts expect the company to announce earnings of ($0.56) per share for the quarter.

Celsion Corporation (NASDAQ CLSN) opened at $2.00 on Friday. Celsion Corporation has a 1-year low of $1.24 and a 1-year high of $12.88.

CLSN has been the subject of a number of research analyst reports. Maxim Group reaffirmed a “hold” rating on shares of Celsion Corporation in a report on Monday, August 7th. Zacks Investment Research raised shares of Celsion Corporation from a “hold” rating to a “buy” rating and set a $1.50 price objective for the company in a research note on Tuesday, August 29th. Finally, ValuEngine raised shares of Celsion Corporation from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $12.63.

TRADEMARK VIOLATION WARNING: “Celsion Corporation (CLSN) Scheduled to Post Quarterly Earnings on Tuesday” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was stolen and republished in violation of United States & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2017/11/12/celsion-corporation-clsn-scheduled-to-post-quarterly-earnings-on-tuesday.html.

About Celsion Corporation

Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).

Earnings History for Celsion Corporation (NASDAQ:CLSN)

Receive News & Ratings for Celsion Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply